New Delhi, Mar 26 (UNI) Ahmedabad-based Troikaa Pharmaceuticals Ltd today said it has received recognition for its in-house research and development facility from the Department of Scientific and Industrial Research (DSIR).
''This accreditation speaks of Troikaa's excellent track record of research work on new drug delivery system and the stupendous infrastructure available,'' said Troikaa Managing Director Ketan Patel.
The R&D centre currently focuses on manufacturing high quality critical care injectibles, tablets and topical preparations through proprietary technology platforms.
Troikaa enjoys an Indian patent of the one ml Diclofenac ampoule and is seeking a patent in another 107 countries across the world.
As a result of this latest recognition, the in-house R&D unit of Troikaa would be eligible for corporate tax exemptions against the expenditure incurred on R&D activities; giving it a further boost. Also it would help to enhance the export of its innovative products, Mr Patel added.
UNI SR MP BD1950